Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FGF-7 CRISPR/Cas9 KO Plasmid (h): sc-401243
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FGF-7 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FGF-7 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FGF-7 Antibody (A-9): sc-515014
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FGF-7 CRISPR/Cas9 KO Plasmid (h) | sc-401243 | 20 µg | $397.00 |
Overview
FGF7 encodes fibroblast growth factor 7 (FGF-7, also known as keratinocyte growth factor), a paracrine ligand produced largely by mesenchymal cells that signals primarily through FGFR2b on epithelial targets. This signaling axis regulates epithelial proliferation, migration, and differentiation and contributes to tissue repair and barrier maintenance through downstream MAPK/ERK, PI3K/AKT, and related growth-factor pathways. Dysregulated FGF7–FGFR2b signaling has been implicated in epithelial hyperplasia, fibrosis-associated remodeling, and tumor–stroma interactions that influence carcinoma growth and invasion. As a model factor in epithelial–mesenchymal crosstalk, FGF-7 is frequently studied in contexts such as wound-healing biology, airway and gastrointestinal epithelium homeostasis, and microenvironment-driven signaling.
FGF-7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FGF7 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FGF7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FGF7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FGF-7 protein expression.
This CRISPR knockout system enables efficient generation of FGF7-deficient cell models for investigation of FGF-7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FGF7 exon(s) critical for FGF-7 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FGF7 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FGF-7 CRISPR/Cas9 KO Plasmid (h) and FGF-7 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FGF7 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FGF-7 HDR Plasmid (h) and FGF-7 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FGF7 homology arms to support homology-directed repair at defined FGF7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.